Standout Papers

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib... 2018 2026 2020 2023 379
  1. Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients (2018)
    Zhe Yang, Nong Yang et al. Clinical Cancer Research

Immediate Impact

1 from Science/Nature 57 standout
Sub-graph 1 of 22

Citing Papers

Transferrin receptor targeting chimeras for membrane protein degradation
2024 StandoutNature
New promises and challenges in the treatment of advanced non-small-cell lung cancer
2024 Standout
17 intermediate papers

Works of Xiaoling Tong being referenced

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
2018 Standout
Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC
2017
and 2 more

Author Peers

Author Last Decade Papers Cites
Xiaoling Tong 699 383 534 20 917
Stephanie Cardarella 889 302 568 13 1.1k
Yuebi Hu 726 527 514 10 996
Satoshi Yoda 647 342 481 26 1.1k
Mary Ann Melnick 665 254 576 14 957
Junpei Takashima 700 201 594 17 919
Emma Donald 792 472 708 11 1.1k
María Sanchez-Ronco 724 328 604 15 1.1k
Qi Li 564 201 537 27 1.0k
Lior Soussan‐Gutman 490 500 515 41 987
Anna Bettini 564 201 570 25 857

All Works

Loading papers...

Rankless by CCL
2026